Devan V Mehrotra (Devan Mehrotra)

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 15

Top Topics

Aortic Dissection

Top Venues

Pharmaceutical statistics

Statistics in medicine

Clinical trials (London, England)

Annals of internal medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Devan V Mehrotra, Rachel Marceau West
Is inadequate risk stratification diluting hazard ratio estimates in randomized clinical trials? Clinical trials (London, England) (2024)
Devan V Mehrotra, Rachel Marceau West
Is inadequate risk stratification diluting hazard ratio estimates in randomized clinical trials? Clinical trials (London, England) (2024)
Rachel Marceau West, Gregory Golm, Devan V Mehrotra
Analysis of composite time-to-event endpoints in cardiovascular outcome trials. Clinical trials (London, England) (2024)
Fang Liu, Qing Zhao, Anthony J Rodgers, Devan V Mehrotra
Calculation of Phase 2 dose-finding study sample size for reliable Phase 3 dose selection. Pharmaceutical statistics (2023)
Hengrui Cai, Wenbin Lu, Rachel Marceau West, Devan V Mehrotra, Lingkang Huang
CAPITAL: Optimal subgroup identification via constrained policy tree search. Statistics in medicine 41 (21) (2022)
Dean A Follmann, Jonathan Fintzi, Michael P Fay, Holly E Janes, Lindsey R Baden, Hana M El Sahly, Thomas R Fleming, Devan V Mehrotra, Lindsay N Carpp, Michal Juraska, David C Benkeser, Deborah J Donnell, Youyi Fong, Shu Han, Ian Hirsch, Ying Huang, Yunda Huang, Ollivier Hyrien, Alex Luedtke, Marco Carone, Martha C Nason, An Vandebosch, Honghong Zhou, Iksung Cho, Erin Gabriel, James G Kublin, Myron S Cohen, Lawrence Corey, Peter B Gilbert, Kathleen M Neuzil
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. Annals of internal medicine 174 (8) (2021)
Björn Bornkamp, Kaspar Rufibach, Jianchang Lin, Yi Liu, Devan V Mehrotra, Satrajit Roychoudhury, Heinz Schmidli, Yue Shentu, Marcel Wolbers
Principal stratum strategy: Potential role in drug development. Pharmaceutical statistics 20 (4) (2021)
Devan V Mehrotra, Holly E Janes, Thomas R Fleming, Paula W Annunziato, Kathleen M Neuzil, Lindsay N Carpp, David C Benkeser, Elizabeth R Brown, Marco Carone, Iksung Cho, Deborah J Donnell, Michael P Fay, Youyi Fong, Shu Han, Ian Hirsch, Ying Huang, Yunda Huang, Ollivier Hyrien, Michal Juraska, Alex Luedtke, Martha C Nason, An Vandebosch, Honghong Zhou, Myron S Cohen, Lawrence Corey, Jonathan Hartzel, Dean A Follmann, Peter B Gilbert
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. Annals of internal medicine 174 (2) (2020)
Devan V Mehrotra, Rachel Marceau West
Survival analysis using a 5-step stratified testing and amalgamation routine (5-STAR) in randomized clinical trials. Statistics in medicine 39 (30) (2020)
Rengyi Xu, Devan V Mehrotra, Pamela A Shaw
Hazard ratio inference in stratified clinical trials with time-to-event endpoints and limited sample size. Pharmaceutical statistics 18 (3) (2019)
Rengyi Xu, Devan V Mehrotra, Pamela A Shaw
Incorporating baseline measurements into the analysis of crossover trials with time-to-event endpoints. Statistics in medicine 37 (23) (2018)
Devan V Mehrotra, Yiwei Zhang
Hazard ratio estimation and inference in clinical trials with many tied event times. Statistics in medicine 37 (25) (2018)
Devan V Mehrotra, Li Fan, Fang Liu, Kuenhi Tsai
Enabling robust assessment of QTc prolongation in early phase clinical trials. Pharmaceutical statistics 16 (3) (2017)
Devan V Mehrotra, Fang Liu, Thomas Permutt
Missing data in clinical trials: control-based mean imputation and sensitivity analysis. Pharmaceutical statistics 16 (5) (2017)
Thomas Jemielita, Mary Putt, Devan V Mehrotra
Improved power in crossover designs through linear combinations of baselines. Statistics in medicine 35 (30) (2016)